An Study of Patients With Ph- Chromosome-negative Relapsed or Refractory Acute Lymphoblastic Leukemia in the US

CompletedOBSERVATIONAL
Enrollment

212

Participants

Timeline

Start Date

June 30, 2016

Primary Completion Date

March 31, 2020

Study Completion Date

March 31, 2020

Conditions
Relapsed/Refractory Acute Lymphoblastic Leukemia
Interventions
OTHER

Other

No intervention other than routine medical care

Trial Locations (19)

10065

Research Site, New York

14263

Research Site, Buffalo

19104

Research Site, Philadelphia

19107

Research Site, Philadelphia

21201

Research Site, Baltimore

21287

Research Site, Baltimore

27157

Research Site, Winston-Salem

44106

Research Site, Cleveland

45229

Research Site, Cincinnati

48201

Research Site, Detroit

50010

Research Site, Ames

60612

Research Site, Chicago

70112

Research Site, New Orleans

78701

Research Site, Austin

85719

Research Site, Tucson

90089

Research Site, Los Angeles

91010

Research Site, Duarte

07601

Research Site, Hackensack

98109-1023

Research Site, Seattle

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Amgen

INDUSTRY